PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
10651689-4	2000	In CTCL there is an accumulating body of evidence to show that 8-methoxypsoralen-treated cells display increased quantities of antigenic peptides at their cell surfaces, and this in turn leads to an enhanced cytotoxic response against the neoplastic T-cell population.	Methoxsalen	63-80	TSPY like 2	Homo sapiens	3-7	
3058601-1	1988	8-Methoxypsoralen (8-MOP) is a photoactivated drug used clinically in the treatment of psoriasis and cutaneous T-cell lymphoma (CTCL).	Methoxsalen	0-17	TSPY like 2	Homo sapiens	128-132	
3058601-1	1988	8-Methoxypsoralen (8-MOP) is a photoactivated drug used clinically in the treatment of psoriasis and cutaneous T-cell lymphoma (CTCL).	Methoxsalen	19-24	TSPY like 2	Homo sapiens	128-132	
6609177-2	1984	In 1975 we started a prospective study on oral methoxsalen photochemotherapy (PUVA) in cutaneous T cell lymphoma (CTCL).	Methoxsalen	47-58	TSPY like 2	Homo sapiens	114-118	
12126205-1	2002	Photopheresis, a leukapheresis-based therapy that combines 8-methoxypsoralen (8-MOP) and ultraviolet-A irradiation, has been shown to be an effective treatment for advanced cutaneous T cell lymphoma (CTCL), but also appears to be effective in certain patients with systemic sclerosis (SSc) and chronic graft versus host disease (cGVHD).	Methoxsalen	59-76	TSPY like 2	Homo sapiens	200-204	
2585773-3	1989	CTCL patients were treated by photochemotherapy with topical 8-methoxypsoralen (8-MOP) followed by VUA irradiation, electron-beam irradiation, or systemic chemotherapy.	Methoxsalen	61-78	TSPY like 2	Homo sapiens	0-4	
2585773-3	1989	CTCL patients were treated by photochemotherapy with topical 8-methoxypsoralen (8-MOP) followed by VUA irradiation, electron-beam irradiation, or systemic chemotherapy.	Methoxsalen	80-85	TSPY like 2	Homo sapiens	0-4	
21778904-6	2011	Extracorporeal photochemotherapy has been shown to be effective in the treatment of CTCL consisting of reinfusion of 3 to 9 x 10 leukocytes, taken from the patient by leukopheresis and treated in an extracorporeal system with 8-methoxypsoralen and UVA.	Methoxsalen	226-243	TSPY like 2	Homo sapiens	84-88	
8534123-1	1995	Extracorporeal photopheresis (ECP) using UVA irradiation of enriched lymphocytes in the presence of 8-methoxypsoralen as a photoactivatable substrate was originally introduced as a therapeutic regimen for cutaneous T-cell lymphoma (CTCL).	Methoxsalen	100-117	TSPY like 2	Homo sapiens	232-236	
10155561-2	1994	Several independent and multicenter trials using lymphapheresis with 8-methoxypsoralen (8-MOP) activated by shortwave ultraviolet light have demonstrated the clinical benefit of this modality for treatment of advanced CTCL.	Methoxsalen	69-86	TSPY like 2	Homo sapiens	218-222	
10155561-2	1994	Several independent and multicenter trials using lymphapheresis with 8-methoxypsoralen (8-MOP) activated by shortwave ultraviolet light have demonstrated the clinical benefit of this modality for treatment of advanced CTCL.	Methoxsalen	88-93	TSPY like 2	Homo sapiens	218-222	
1914077-1	1991	Treatment of peripheral blood mononuclear cells with 8-methoxypsoralen (8-MOP) and ultraviolet light, a procedure known as PUVA, has been found to be useful in the management of systemically disseminated cutaneous T-cell lymphoma (CTCL).	Methoxsalen	53-70	TSPY like 2	Homo sapiens	231-235	
1914077-1	1991	Treatment of peripheral blood mononuclear cells with 8-methoxypsoralen (8-MOP) and ultraviolet light, a procedure known as PUVA, has been found to be useful in the management of systemically disseminated cutaneous T-cell lymphoma (CTCL).	Methoxsalen	72-77	TSPY like 2	Homo sapiens	231-235